Tumor mutational load predicts survival after immunotherapy across multiple cancer types
2019 · Nature Genetics · 4,300 citations
https://doi.org/10.1038/s41588-018-0312-8
C
Christopher A. Klebanoff
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
234
Papers
24.7K
Citations
56
h-index
84
i10-index
Christopher A. Klebanoff is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: CAR-T cell therapy research & Immunotherapy and Immune Responses & Cancer Immunotherapy and Biomarkers. The author has an h-index of 56, co-authored 199 publications.
ORCID: 0000-0001-9645-3896Papers by this author
worksInhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function
2013 · Journal of Clinical Investigation · 908 citations
https://doi.org/10.1172/jci69589
Clinical implications of T cell exhaustion for cancer immunotherapy
2022 · Nature Reviews Clinical Oncology · 875 citations
https://doi.org/10.1038/s41571-022-00689-z
T cell stemness and dysfunction in tumors are triggered by a common mechanism
2019 · Science · 511 citations
https://doi.org/10.1126/science.aau0135
CD8<sup>+</sup> T‐cell memory in tumor immunology and immunotherapy
2006 · Immunological Reviews · 499 citations
https://doi.org/10.1111/j.0105-2896.2006.00391.x
Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis
2019 · Annals of Oncology · 238 citations
https://doi.org/10.1093/annonc/mdz398
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat